Drug developer Berlin Cures announced the successful completion of its Phase 1 study of its lead candidate BC 007 for the treatment of cardiomyopathy. BC 007 is a DNA-based aptamer compound that binds to and eliminates functional pathogenic autoantibodies targeting the beta-1 adrenoceptor. Even a moderate dose was able to eliminate the autoantibodies which are present in the majority of heart failure patients. BC 007 continues to show an excellent safety profile without any serious adverse events or any signs of allergic reactions of the 74 treated individuals. This outcome provides an optimistic outlook for the upcoming Phase 2 trial.
The results confirm the potential of Berlin Cures’ innovative therapeutic concept, which represents the first causal treatment approach to heart failure. The specific elimination of autoantibodies could provide a compelling alternative to expensive and stressful dialysis or cardiac assist devices.
Further information:
Berlin Cures’ press release